+关注
绝世小孬
暂无个人介绍
IP属地：未知
18
关注
0
粉丝
1
主题
0
勋章
主贴
热门
绝世小孬
2020-02-12
$慧择控股(HUIZ)$
辣鸡
绝世小孬
2020-02-08
瑞德西韦专利之争
吉利德回应瑞德西韦专利：2016年就已全球申请
去老虎APP查看更多动态
{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":3544237421858208,"uuid":"3544237421858208","gmtCreate":1581151718261,"gmtModify":1581151718261,"name":"绝世小孬","pinyin":"jsxnjueshixiaonao","introduction":"","introductionEn":"","signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":"https://static.tigerbbs.com/e6295840391b9cdc17115677ba51429c","hatId":"tiger_head_frame","hatName":"小虎头像框","vip":1,"status":2,"fanSize":0,"headSize":18,"tweetSize":2,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":1,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-2","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"资深虎友","description":"加入老虎社区1000天","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.11.08","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":2,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":1,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"hot","tweets":[{"id":917010732,"gmtCreate":1581522338126,"gmtModify":1704344445118,"author":{"id":"3544237421858208","authorId":"3544237421858208","name":"绝世小孬","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/HUIZ\">$慧择控股(HUIZ)$</a> 辣鸡","listText":"<a href=\"https://laohu8.com/S/HUIZ\">$慧择控股(HUIZ)$</a> 辣鸡","text":"$慧择控股(HUIZ)$ 辣鸡","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/917010732","isVote":1,"tweetType":1,"viewCount":590,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":914812856,"gmtCreate":1581152820475,"gmtModify":1704343620862,"author":{"id":"3544237421858208","authorId":"3544237421858208","name":"绝世小孬","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"瑞德西韦专利之争","listText":"瑞德西韦专利之争","text":"瑞德西韦专利之争","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/914812856","repostId":"2009231175","repostType":2,"isVote":1,"tweetType":1,"viewCount":1051,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":917010732,"gmtCreate":1581522338126,"gmtModify":1704344445118,"author":{"id":"3544237421858208","authorId":"3544237421858208","name":"绝世小孬","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/HUIZ\">$慧择控股(HUIZ)$</a> 辣鸡","listText":"<a href=\"https://laohu8.com/S/HUIZ\">$慧择控股(HUIZ)$</a> 辣鸡","text":"$慧择控股(HUIZ)$ 辣鸡","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/917010732","isVote":1,"tweetType":1,"viewCount":590,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":914812856,"gmtCreate":1581152820475,"gmtModify":1704343620862,"author":{"id":"3544237421858208","authorId":"3544237421858208","name":"绝世小孬","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"瑞德西韦专利之争","listText":"瑞德西韦专利之争","text":"瑞德西韦专利之争","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/914812856","repostId":"2009231175","repostType":2,"repost":{"id":"2009231175","pubTimestamp":1580964000,"share":"https://www.laohu8.com/m/news/2009231175?lang=&edition=full","pubTime":"2020-02-06 12:40","market":"hk","language":"zh","title":"吉利德回应瑞德西韦专利：2016年就已全球申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2009231175","media":"第一财经","summary":"针对武汉病毒所就吉利德药物瑞德西韦（Remdesivir）的抗新型冠状病毒感染肺炎的新适应症申请中国专利发明一事，2月6日第一财经记者从吉利德方面独家获悉，吉利德在2016年就已经就该化合物以及针对冠","content":"<div>\n<p>针对武汉病毒所就吉利德药物瑞德西韦（Remdesivir）的抗新型冠状病毒感染肺炎的新适应症申请中国专利发明一事，2月6日第一财经记者从吉利德方面独家获悉，吉利德在2016年就已经就该化合物以及针对冠状病毒的用途在全球申请了专利，也包括中国。但是中国的申请还有待批准。\n吉利德称：“吉利德研发了瑞德西韦（Remdesivir），并在美国、中国及世界其他地区拥有专利。2016年，针对瑞德西韦（...</p>\n\n<a href=\"https://finance.sina.com.cn/chanjing/gsnews/2020-02-06/doc-iimxxste9261497.shtml\">Web Link</a>\n\n</div>\n","source":"sina","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>吉利德回应瑞德西韦专利：2016年就已全球申请</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n吉利德回应瑞德西韦专利：2016年就已全球申请\n</h2>\n\n<h4 class=\"meta\">\n\n\n2020-02-06 12:40 北京时间 <a href=https://finance.sina.com.cn/chanjing/gsnews/2020-02-06/doc-iimxxste9261497.shtml><strong>第一财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>针对武汉病毒所就吉利德药物瑞德西韦（Remdesivir）的抗新型冠状病毒感染肺炎的新适应症申请中国专利发明一事，2月6日第一财经记者从吉利德方面独家获悉，吉利德在2016年就已经就该化合物以及针对冠状病毒的用途在全球申请了专利，也包括中国。但是中国的申请还有待批准。\n吉利德称：“吉利德研发了瑞德西韦（Remdesivir），并在美国、中国及世界其他地区拥有专利。2016年，针对瑞德西韦（...</p>\n\n<a href=\"https://finance.sina.com.cn/chanjing/gsnews/2020-02-06/doc-iimxxste9261497.shtml\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/42e9f535bb806f3f9b723fb2b59a89b7","relate_stocks":{},"source_url":"https://finance.sina.com.cn/chanjing/gsnews/2020-02-06/doc-iimxxste9261497.shtml","is_english":false,"share_image_url":"https://static.laohu8.com/b0d1b7e8843deea78cc308b15114de44","article_id":"2009231175","content_text":"针对武汉病毒所就吉利德药物瑞德西韦（Remdesivir）的抗新型冠状病毒感染肺炎的新适应症申请中国专利发明一事，2月6日第一财经记者从吉利德方面独家获悉，吉利德在2016年就已经就该化合物以及针对冠状病毒的用途在全球申请了专利，也包括中国。但是中国的申请还有待批准。\n吉利德称：“吉利德研发了瑞德西韦（Remdesivir），并在美国、中国及世界其他地区拥有专利。2016年，针对瑞德西韦（Remdesivir）在冠状病毒上的应用，吉利德在中国以及全球申请了更多的专利。在中国，对于冠状病毒应用的专利申请尚待批准。”\n吉利德还表示：“已经注意到武汉病毒研究所就相关药物的应用申请专利的情况。”但是强调，现阶段讨论任何强制许可或其他类型许可还为时过早。“我们并未与监管部门就吉利德的生产供应成本或财务回报进行过任何的讨论。”公司对第一财经记者表示，“我们现在的关注焦点是尽快确认Remdesivir对新型冠状病毒的潜在治疗效果，加快生产供应，以应对未来潜在的供给需求。”\n吉利德没有表示是否会对武汉病毒研究所的专利提出挑战。公司称：“吉利德无权干涉专利局是否向中国研究人员授予专利。武汉病毒研究所的专利申请是在吉利德提交申请的三年多时间之后提交的，对这份申请的考量将会综合目前对于该合成药物已知的了解和正在申请中的专利。我们无法对研究人员专利申请的细节发表评论，因为专利申请内容在18个月之后才会公布。”\n此前，武汉病毒研究所在2月4日发表的一份声明中称：“对在我国尚未上市，且具有知识产权壁垒的药物瑞得西韦，我们依据国际惯例，从保护国家利益的角度出发，在1月21日申报了中国发明专利（抗2019新型冠状病毒的用途），并将通过PCT（专利合作协定）途径进入全球主要国家。如果国外相关企业有意向为我国疫情防控做出贡献，我们双方一致同意在国家需要的情况下，暂不要求实施专利所主张的权利。”\n第一财经记者2月6日上午致电武汉病毒研究所瑞德西韦论文共同第一作者、武汉病毒研究所王曼丽研究员，一直无人接听；2月5日晚间给该所发送的邮件也未得到回复。","news_type":1},"isVote":1,"tweetType":1,"viewCount":1051,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}
